Manning & Napier Group's MRK Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 186,754 shares of Merck & Co., Inc. (MRK) worth $15.67 M, representing 0.20% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Manning & Napier Group has maintained a long-term strategic position in MRK, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2015, adding 6.23 M shares. Largest reduction occurred in Q4 2015, reducing 5.87 M shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Merck & Co (MRK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Merck & Co (MRK) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +439,839 | Add 0.00% | 439,838 | $44.32 |
| Q3 2013 | +2,467 | Add 0.56% | 442,305 | $45.43 |
| Q4 2013 | -13,482 | Reduce 3.05% | 428,823 | $47.75 |
| Q1 2014 | -58,361 | Reduce 13.61% | 370,462 | $54.16 |
| Q2 2014 | +27,979 | Add 7.55% | 398,441 | $55.20 |
| Q3 2014 | -2,937 | Reduce 0.74% | 395,504 | $56.56 |
| Q4 2014 | +22,894 | Add 5.79% | 418,398 | $54.19 |
| Q1 2015 | -923 | Reduce 0.22% | 417,475 | $54.84 |
| Q2 2015 | +6.23 M | Add 1493.37% | 6.65 M | $54.32 |
| Q3 2015 | -176,977 | Reduce 2.66% | 6.47 M | $47.13 |
| Q4 2015 | -5.87 M | Reduce 90.63% | 606,593 | $50.40 |
| Q1 2016 | -80,960 | Reduce 13.35% | 525,633 | $50.48 |
| Q2 2016 | -101,823 | Reduce 19.37% | 423,810 | $54.97 |
| Q3 2016 | -71,707 | Reduce 16.92% | 352,103 | $59.55 |
| Q4 2016 | +45,749 | Add 12.99% | 397,852 | $56.17 |
| Q1 2017 | +3,861 | Add 0.97% | 401,713 | $60.63 |
| Q2 2017 | +60,485 | Add 15.06% | 462,198 | $61.15 |
| Q3 2017 | +14,718 | Add 3.18% | 476,916 | $61.09 |
| Q4 2017 | +465,391 | Add 0.00% | 465,390 | $53.69 |
| Q1 2018 | +1.55 M | Add 332.23% | 2.01 M | $51.97 |
| Q2 2018 | -108,834 | Reduce 5.41% | 1.9 M | $57.92 |
| Q3 2018 | -54,304 | Reduce 2.85% | 1.85 M | $67.69 |
| Q4 2018 | -109,341 | Reduce 5.92% | 1.74 M | $72.91 |
| Q1 2019 | -67,585 | Reduce 3.89% | 1.67 M | $79.36 |
| Q2 2019 | -10,264 | Reduce 0.61% | 1.66 M | $80.01 |
| Q3 2019 | -498,623 | Reduce 30.02% | 1.16 M | $80.32 |
| Q4 2019 | +52,923 | Add 4.55% | 1.22 M | $86.78 |
| Q1 2020 | -389,649 | Reduce 32.06% | 825,862 | $73.41 |
| Q2 2020 | +4,501 | Add 0.55% | 830,363 | $73.79 |
| Q3 2020 | -139,053 | Reduce 16.75% | 691,310 | $79.15 |
| Q4 2020 | -21,602 | Reduce 3.12% | 669,708 | $78.05 |
| Q1 2021 | +11,828 | Add 1.77% | 681,536 | $73.56 |
| Q2 2021 | +49,985 | Add 7.33% | 731,521 | $77.77 |
| Q3 2021 | -3,594 | Reduce 0.49% | 727,927 | $75.11 |
| Q4 2021 | -29,736 | Reduce 4.09% | 698,191 | $76.64 |
| Q1 2022 | -34,260 | Reduce 4.91% | 663,931 | $82.05 |
| Q2 2022 | -118,484 | Reduce 17.85% | 545,447 | $91.17 |
| Q3 2022 | -9,885 | Reduce 1.81% | 535,562 | $86.12 |
| Q4 2022 | -13,125 | Reduce 2.45% | 522,437 | $110.95 |
| Q1 2023 | -2,612 | Reduce 0.50% | 519,825 | $106.39 |
| Q2 2023 | +46,220 | Add 8.89% | 566,045 | $115.39 |
| Q3 2023 | -19,496 | Reduce 3.44% | 546,549 | $102.95 |
| Q4 2023 | -68,741 | Reduce 12.58% | 477,808 | $109.02 |
| Q1 2024 | -44,452 | Reduce 9.30% | 433,356 | $131.95 |
| Q4 2024 | +74,616 | New Buy | 74,616 | $99.48 |
| Q1 2025 | -6,332 | Reduce 8.49% | 68,284 | $89.76 |
| Q2 2025 | +189,837 | Add 278.01% | 258,121 | $79.16 |
| Q3 2025 | -71,367 | Reduce 27.65% | 186,754 | $83.93 |
Manning & Napier Group's Merck & Co Investment FAQs
Manning & Napier Group first purchased Merck & Co., Inc. (MRK) in Q2 2013, acquiring 439,838 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Merck & Co., Inc. (MRK) for 50 quarters since Q2 2013.
Manning & Napier Group's largest addition to Merck & Co., Inc. (MRK) was in Q2 2015, adding 6,651,906 shares worth $361.35 M.
According to the latest 13F filing for Q3 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 186,754 shares of Merck & Co., Inc. (MRK), valued at approximately $15.67 M.
As of the Q3 2025 filing, Merck & Co., Inc. (MRK) represents approximately 0.20% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Merck & Co., Inc. (MRK) was 6,651,906 shares, as reported at the end of Q2 2015.